In the current scenario type two diabetes mellitus and hypertension have become prevalent in large number of population. But there are many patients which are suffering from Type II Diabetes Mellitus as well as hypertension. Such condition is called co-existent Type II Diabetes Mellitus and Hypertension. In the present work an attempt is made to treat co-existent type II Diabetes Mellitus and hypertension by formulating a Bilayer tablet of Teneligliptin and Telmisartan. Both drugs are sustained released to give a day long relief to the patients and to also reduce the dose frequency. Both the layers of the tablets were formulated by wet granulation method. The granules were tested for angle of repose, bulk density, tapped density, compressibility and Hausner's ratio to check their efficacy. Eleven different types of formulations were made using various polymers and excipients with the drugs such as PVP K30, HPMC K4M, Starch, Crospovidone, Lactose, Mannitol, Talc and Magnesium Stearate. From these 11 formulations F6 showed better tablet characteristics and drug release rate than other formulations. Thus F6 is the best formulation in this study. Biological screening of the drugs combination of Teneligliptin and Telmisartan was also done to check the presence of antidiabetic activity of the combination which showed positive results.
INTRODUCTION:
In this modern world of faster and hectic lives, eating healthy and staying fit is ignored. Such ignorance may lead to various harmful diseases and disorders. Diabetes mellitus is such kind of disorder which if not managed properly may prove fatal. Type II Diabetes mellitus is the most harmful type of diabetes as the body of the patient becomes insulin resistant. Also hypertension is present in large number of populations. But when these two severe diseases are present coexistently in an individual, additional care is needed to be taken. Coexistent Type Two Diabetes Mellitus (TTDM) and hypertension exposes patients to severe co-morbidities.
Hypertension (HTN) is present in more than 50% of patients with diabetes mellitus (DM) and contributes significantly to both micro and macrovascular disease in DM. Indeed, the risk for cardiovascular disease (CVD) is four-fold higher in patients with both DM and HTN as compared to the normotensive non-diabetic controls. To this point, a meta-analysis of 102 prospective studies involving 698,782 individuals found that DM is responsible for approximately a two-fold increased risk for coronary heart disease, stroke and deaths from cardiovascular cause, including heart failure, cardiac arrhythmia, hypertensive disease, etc. In developed countries 60-65% prevalence is seen in coexistent type II diabetes mellitus and hypertension. Complex polypharmacy suggested by international organizations leads to the increased pill burden and decreased patient compliance which leads to worsening of conditions 1, 2 .
Hence there is a need for a combination of antidiabetic and antihypertensive drugs for the treatment of coexistent type two diabetes mellitus and hypertension.
MATERIALS:-
Teneligliptin was provided as gift sample from Lupin Pharmaceuticals Limited, Pune whereas Telmisartan was obtained from Abbott Healthcare Pvt. Ltd. Himachal Pradesh as gift samples. Polymers and excipients such as HPMC K4M, PvpK30, crospovidone, talc etc were purchased from JP. Fine chemicals and Loba Chemise Pvt. Ltd.
METHODS:-
Various techniques can be used to formulate bilayer tablets. Wet granulation is one of the techniques used to formulate the two layers of tablets. Wet granules of both layers are formulated individually. Wet granulation techniques have various advantages. Hence it is a method of choice for many tablet formulations. It enhances the flow properties of powder mix. It avoids segregation of powder components during tabletting or storage. It also reduces cross-contamination and hazard associated with the generation of toxic dust that may arise during manufacturing process. Wet granulation not only improves the compression characteristics of drug substances as well as improves the appearance of the final product. Wet granulation involves use of water for granulation. Aqueous binder solution is added to the dough mass and then sieved to produce the required size of granules. Tablets made from wet granulation techniques have better hardness and appearance then directly compressed tablets. Conventional equipment, commonly available excipients and a limited number of processing steps are involved in direct compression. Also high doses can be accommodated. Moreover this technique improves the dissolution characteristics of the poorly water-soluble drugs by allowing uniform distribution of the binder that acts as a wetting agent and enable adequate wetting of the drug substance during granulation. It also increases the chances of adequate and uniform contact between the drug and hydrophilic polymer for better dissolution. These improved granule characteristics also results in even erosion of tablets during dissolution (4, 15) .


Preparation of Tablet by Wet Granulation :
 Wet Granulation of Sustained Release Telmisartan Layer :-Wet granulation is the most widely used to prepare tablets. Formulation with different binders was compressed into tablets. The required quantities of Telmisartan ,starch ,lactose monohydrate ,HPMC K4M, crospovidone were weighed accurately using analytical balance and were mixed well using laboratory conditions. The aqueous binder solution was added and mixed thoroughly to form dough mass. Carmiosine Colour was added to the aqueous binder solution for Telmisartan granules to provide visual detection of two different layers in the bilayer tablets. The formed mass was passed through Mesh no.12 to obtain wet granules .The wet Granules were dried in a hot air oven at 300 c temperatures. then the dried granules were passed through mesh no.16 to break aggregates. Talc & magnesium stearate were passed through mesh no.100 on to dry granules and blended in a polyethylene bag .The Tablet granules were then compressed using compression machine at punch No. 5 (11, 15) .

Wet Granulation of Sustained Release Teneligliptin Layer :-Wet granulation is done for this layer of Bilayer tablet too. This layer consists of drug/API. Teneligliptin(20mg) and various excipients which act as binders, diluents and lubricants in the formulation. These are starch, mannitol and magnesium stearate respectively. HPMC K4M is the sustained releasing agent. The aqueous binder solution was added and mixed thoroughly to form a dough mass. The formed dough mass was passed through Mesh no.12 to obtain wet granules of Teneligliptin layer. The wet granules were dried in a hot air oven at 300 o c temperatures. On drying, the dried granules were passed through mesh no.16 to break aggregates if formed. Talc & magnesium stearate were passed through mesh no.100 on to dry granules and blended in the polyethylene bag kept for these granules. The Tablet granules were then compressed using compression machine at punch No. 5 over the Telmisartan layer. 3  3  3  3  3  3  3  3  3  3  3  9  Talcum  3  3  3  3  3  3  3  3  3  3  3 The following parameters are determined.
Thus, The Bilayer Tablet is formed by the Above Mentioned Processes
Compositions of Bilayer Tablets
Angle of Repose:
The angle of repose has been used to characterize the flow properties of solids. This is the maximum angle possible between surface of pile of powder or granules and the horizontal plane.
Bulk Density
The ratio of mass (weight) to volume is known as the bulk density of material. The bulk density is obtained by dividing the weight of the sample in grams by final volume in cm 3 .
Tapped Density
Tapped density is determined by placing a graduated cylinder containing a known mass of drug on a mechanical tapper apparatus which is operated for fixed number of taps (~ 100) until a powder bed volume has reached the minimum.
Compressibility Index
The compressibility index of the powder was determined by Carr's index. The Carr's index is determined from the tapped density and poured density (bulk density) as per its formula.
Hausner's Ratio
Hausner's ratio is determined from the ratio of tapped density to bulk density using its standard formula.
 Evaluation of Post Compression Parameter: 1) General Appearance:
General appearance would include a number of aspects like size, shape, odor, taste, texture, legibility and identifying marks.
2) Size and Shape:
Different shapes and size of tablet are available in the market they are manufactured in order. The shape and size of a tablet would vary based on tooling used in the tablet manufacturing. In laboratory scale tablet size measured by the Vanier caliper. Tablet thickness should be controlled within ±5% variation of a standard value.
3) Hardness:
Tablet hardness and strength are the essential to see that the tablet can with the shock and stress during manufacturing packaging and transportation, and while handle by the patient. For each formulation, the hardness of tablet determined using the Monsanto hardness tester.
4) Friability:
Friability is the test for a tablet those whether the tablet is stable to abrasion or not, it is tested by using Roche Friabilitor.
5) Weight Variation:
Weight variation test is performed to check that the manufactured tablets have a uniform weight. For a tablet to pass the test not more than 2 tablets should lie out of the specified percentage and if no tablet differ by more than two times the percentage limit. From each batch 3 tablets were weighed each containing 10 mg of tablet were taken. Tablets were triturated in motor and quantity of powder equivalent to 10 mg of tablet powder was transferred to 100 ml volumetric flask. Sufficient quantity of Phosphate buffer solution P H 6.8 was added with shaking and volume was made up to the mark and filtered through whatman filter paper. Further dilutions were made in concentration 2, 4, 6, 8, 10ug/ml. then absorbance was recorded at different wavelength of drugs such as (Teneligliptin at 243.6 nm and Telmisartan at 295 nm) against phosphate buffer solution P H 6.8 as a blank.
7)
In vitro Disintegration Time (6, 14) :
In vitro disintegration time of the tablet was determined using USP disintegration test apparatus as per I.P. specifications. It is determined by using USP device which consisted of 6 glass tubes that are 3 inches long. Open at one end and held against 10 mesh screen at the bottom end of basket rack assembly. To test for disintegration time, one tablet is placed in each tube and the basket arch is positioned in a 1 liter basket assembly up and down. To compliance with the USP standard, all tablet must disintegrate and all particles must pass through the 10 mesh in the time specified. (56, 58) (15, 18) :
8) In vitro Dissolution Study
Dissolution profiles of bilayer tablets were determined using the USP method II with paddle speed at 50 rpm. The media used in dissolution apparatus was phosphate buffer P H 6.8 (900ml) and maintained it at 37 ± 1 0 C. the 2ml of sample were withdrawn at 0, 30, 60, 90, 120, 180, 240, 300, 360, 420 minutes time intervals.. 5ml diluted with 10ml of phosphate buffer solution, and analyzed at 243.6 nm and 295nm using UV-Visible double beam spectrophotometer (JASCO V-630). ICH recommends carrying out stress testing on the drug substance to establish its inherent characteristics and support the solubility of the proposed analytical procedure. Stability study at room temperature is the method of determining the actual shelf life of the product. Unfortunately it is difficult to make an accurate expiration date prediction until 2-3 yrs. Of data are generated, which will require long shelf life conditions. Hence accelerated stability studied were carried out at elevated temperature will help to determine shelf life within a lesser period of time. The prepared tablets were evaluated for a period of one to three month as per ICH Guidelines. Apparatus: -Glucometer, Disposable syringe (1ml tuberculin syringe), feeding needles (for oral dose), Polypropylene cage.
Procedure-
Wistar rats either sex weighing between 150-200gm were used. The animals were housed under controlled conditions with standard diet and water. The animals were kept fasted for 24hrs with water , diabetes was induced by Alloxan monohydrate (120mg/kg i.p) in normal saline solution.
A 5% dextrose solution was given in feeding bottle for a day to overcome early hypoglycemic phase. The blood glucose level was monitored by taking blood tail tip cut method on glucometer.
After 72 hrs,the animals showing blood glucose level beyond 150mg/dl were segregated and were divided into 3 groups.viz…(i) vehicle treated group (ii) standard treated group, (iii) drug treated group comprised 5 subgroups for 3 test combinations. Each group as well as subgroup comprised of 6 animals.The doses of combination of Teneligliptin and Telmisartan to be administered to wistar rats based on the available references of individual drugs was calculated. (for acute study). bleeding from the vein has stopped. If the blood does not stops, clotting agent can be used to stop the blood flow. 4) Throw or dispose the needle well. If the animal is administered with an anesthetia, monitor the animal till it is fully awake and it is able to move normally. Repetitive bleeds for blood collection may be performed by insertion of the needle further up the tail. 
B] Blood Sample Collection From Tail Vein:-
C] Methodology:-Collection of Blood:-
RESULTS AND DISCUSSION: IR Spectroscopy Analysis:
 The IR Spectrum of the drug agrees with its chemical structure 6-chloro-4hydroxy-2-methyl-N-2-pyridyl-2H-thieno-[2, 3 The IR Spectrum of the drug agree with the chemical structure (RS)-2-(3-benzoylphenyl)-propionic acid. Thus justified that there is no or minimal interaction of binders with the drug molecules. Hence there is no obstacle in using these binders to formulate the tablet.
Differential Scanning Calorimetry:
The DSC thermogram of Teneligliptin showed a sharp exothermic peak at 210. 
Calibration Curve of Teneligiptin:
The standard calibration curve shows the slope of 0.065 and correlation coefficient of 0.998. The curve was found to be linear in the concentration range of 2, 4, 6, 8, 10μg/ml at 243.6 nm. The calculation of drug content, in vivo dissolution study was based on the calibration curve. The standard calibration curve of Telmisartan was obtained by plotting Absorbance vs. Concentration. Table No. 12 shown the absorbance values of Telmisartan. The standard curve is shown in Figure 9 .9. The standard calibration curve shows the slope of 0.075 and correlation coefficient of 0.996. The curve was found to be linear in the concentration range of 2, 4, 6, 8, 10μg/ml at 295 nm. The calculation of drug content, in vivo dissolution study was based on the calibration curve. 
Characterization of Granules of API and Excipients:
For each type of preliminary formulation blends, blends of API and Excipients were prepared and evaluated for various parameters as explained earlier. Stability studies of the Best Formulation F6 was carried out by keeping the tablets at room temperature and 40 0 C ±2 0 C/ 75 ±5 % RH (stability chamber) for 30 days. From the stability studies it was found that formulation were stable at room temperature and 40 0 C ±2 0 C/ 75 ±5 % RH for a period of 60 days. There was no appreciable and highlighting change in physical properties, drug release and drug content during the testing period. Thus the test indicated stability of formulations.
Physical Appearance:
Color: unchanged. Odour: unchanged The antidiabetic activity is held and by the observation of blood glucose levels we can say that the Teneligliptin and Telmisartan Combination is useful in the activity.
CONCLUSION:
On the basis of the study, selection of drug candidate and the type of formulation lead to the formulation of Bilayer Tablets to treat Co-existent Type II Diabetes Mellitus and Hypertension were formulated successfully. The addition of magnesium stearate which produce satisfactory results for flow property of powders. Addition of crospovidone improved drug release of Telmisartan layer. The Preformulation study revealed the purity of drug and also it confirmed the stability of drug with excipient hence proved to be compatible there.
All the tablet formulations showed satisfactory results with respect to hardness, friability, disintegration time, drug content and In-vitro dissolution studies. The binder, filler, diluents, lubricants used in the formulations which improve the tablet quality and sustained release agent improve the disintegration and dissolution property of tablets. The powder was granulated by wet granulation and the second layer was compressed above the compressed first layer, it is a good method used for the compression of bilayer tablets. Wet granulation is the best method for formulation of such bilayer tablets. The results obtained in Biological Studies revealed that the present drug combination shows antidiabetic activity. Telmisartan does not hinders the antidiabetic activity of Teneligliptin when taken in combination. Thus, there is no Drug-Drug Interaction between Teneligliptin and Telmisartan. Therefore, this research work concludes the successful was shown the "Formulation and Evaluation of Teneligliptin and Telmisartan Bilayer Tablets for the Treatment of Coexistent Type II Diabetes Mellitus and Hypertension".
